Goldman Sachs Maintains Buy on Enliven Therapeutics, Raises Price Target to $80
Benzinga Newsdesk 2 months ago
Analyst RatingsNewsPrice Target
Goldman Sachs analyst Salveen Richter maintains Enliven Therapeutics (NASDAQ:ELVN) with a Buy and raises the price target from $67 to $80.
Goldman Sachs analyst Salveen Richter maintains Enliven Therapeutics (NASDAQ:ELVN) with a Buy and raises the price target from $67 to $80.